Novavax has launched a phase 1/2 trial in Australia evaluating the safety and immunogenicity of a combination influenza and COVID-19 vaccine.

The study will assess Novavax’s COVID-19 vaccine candidate, NVX-CoV2373, plus its flu shot, NanoFlu, along with its Matrix-M adjuvant in 640 healthy adults aged 50 to 70.

Participants must have either previously been infected with the SARS‑CoV‑2 virus or have been vaccinated at least eight weeks before the study begins, the Gaithersburg, Md., drugmaker said. Results are expected during the first half of 2022.